The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
Scope
This report gives an important monthly update on the pharmaceutical outsourcing industry, based on analysis from the analyst's experts and our databases covering deals, companies, drugs, financials, news, clinical trials, and more. This report is required reading for:- CMO executives and strategic decision-makers: to improve understanding of the CMO industry and provide a critical input for strategic planning efforts.
- Sourcing and procurement executives in bio/pharmaceutical companies: to improve understanding of crucial components of the supply base that will provide insights for supplier selection and management.
- Investors, advisors, and consultants: they can gain a deeper understanding of the CMO market and important insights for identifying potential investment targets.
Reasons to Buy
- Understand current trends and equip yourself with forward-thinking strategies to navigate challenges and capitalise on emerging trends driving the pharmaceutical manufacturing industry. Use our radar to identify developments and innovations with high impact.
- Discover the latest opportunities and threats in the contract manufacturing industry, based on clinical trials and regulatory decisions.
- Learn about the past quarter’s M&A and financing deals in the manufacturing space.
- Identify the latest contract service agreements.
- Develop your competitor or market intelligence by reading about inspection outcomes and facility investments.
- Stay ahead of disruption with updates on supply chain obstacles and new regulations.
Table of Contents
- Industry Trends
- Navigating Uncertainty: The Future of Vaccine Oversight Amid CDC Firings
- ADCs on the Rise: MilliporeSigma, Lonza Invest in Manufacturing While BioNTech Adds CMOs Ahead of FDA Filing
- National Resilience to Close 6 Sites After Misjudging Demand
- Regulatory trends in brief
- Industry Analysis
- Contract service agreements
- Contract manufacturing - opportunities and threats
- Quarterly mergers, acquisitions, and financing - Q2 2025
- Value Chain
- API chemical
- API biologics - protein and peptide
- API biologics - cell, gene, vaccine, and virus
- Commercial dose manufacturing and packaging
- Clinical dose manufacturing and packaging
- Analytical services
- About the Analyst
- About the Authors
- Contact the Publisher
Table 1: Contract service agreements
Table 2: Contract manufacturing: opportunities and threats - potentially positive
Table 3: Contract manufacturing: opportunities and threats - potentially negative
Table 4: Mergers, acquisitions, and financing - Q2 2025
List of Figures
Figure 1: Historical and projected ADC market, 2020-30
Figure 2: Current ADC landscape, by development stage
Figure 3: Contract service agreements by deal geography, by volume
Figure 4: Deals by deal geography, by volume
Figure 5: The contract manufacturing value chain
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Moderna
- MilliporeSigma
- Simtra BioPharma Solutions
- Carbogen AMCIS
- BioNTech
- National Resilience Inc
- Curia Global Inc
- Teva
- Lonza
- Famar Health Care Services
- PCI Pharma Services
- WuXi Biologics
- Samsung Biologics
- SK Bioscience
- Dr. Reddy's Laboratories
- Cellares Corp
- Viralgen Vector Core
- Thermo Fisher Scientific
- Fareva SA
- Recipharm
- Fujifilm Diosynth Biotechnologies
- Piramal Pharma Solutions
- Eurofins Scientific
- Bionique Testing Laboratories
- SK Pharmteco
- Svar Life Science
- Ingenza Ltd
- 3PBIOVIAN
- Made Scientific Inc
- VGXI Inc
- GSK plc
- Novavax
- Bristol-Myers Squibb
- Agenus Inc
- Zydus Lifesciences
- Altheia Science
- Kincell Bio
- Anemocyte Srl
- Facet Life Sciences
- eXmoor Pharma Concepts
